BVS 857
Alternative Names: BVS-857Latest Information Update: 27 Sep 2021
At a glance
- Originator Novartis Pharmaceuticals Corporation
- Class Antihyperglycaemics; Growth factors
- Mechanism of Action Insulin-like growth factor I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Burns; Insulin resistance; X-linked bulbo-spinal atrophy
Most Recent Events
- 27 Sep 2021 No development reported - Phase-II for Burns in USA (IV)
- 27 Sep 2021 No development reported - Phase-II for Burns in USA (SC)
- 27 Sep 2021 No development reported - Phase-II for X-linked bulbo-spinal atrophy in Denmark (IV)